2seventy bio and JW Therapeutics ink strategic partnership

US immuno-oncology cell therapy company 2seventy bio’s (Nasdaq: TSVT) shares gained 3.5% to $16.00 this morning, as it announced a strategic alliance with Chinese biotech JW Therapeutics (HKEX: 2126) to establish a translational and clinical cell therapy development platform designed to more rapidly explore T cell-based immunotherapy therapy products in the Chinese mainland, Hong Kong (China), and Macao (China).

2seventy bio was spun out of bluebird bio (Nasdaq: BLUE) in 2021 and in March this year it secured a $170 million financing in a private placement.

“The true patient benefit of this collaboration lies in the ability to establish additional capabilities to rapidly test, learn and progress our innovative cell therapy programs,” said Steve Bernstein, chief medical officer, 2seventy bio, adding: “JW Therapeutics possesses extensive understanding of the unmet medical needs of the population and the regulatory affairs process in C hina as well as the clinical development pathways. The opportunity to bring together our distinctive areas of experience to create a differentiated platform supports our goal of bringing new therapies to patients as quickly as possible.”